Last reviewed · How we verify
Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
Venetoclax-Decitabine/Azacitidine-Aclarubicin Association is a BCL-2 inhibitor Small molecule drug developed by The First Affiliated Hospital with Nanjing Medical University. It is currently in Phase 3 development for Acute myeloid leukemia (AML).
Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine-Aclarubicin combination works by inducing DNA hypomethylation and promoting apoptosis in cancer cells.
Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine-Aclarubicin combination works by inducing DNA hypomethylation and promoting apoptosis in cancer cells. Used for Acute myeloid leukemia (AML).
At a glance
| Generic name | Venetoclax-Decitabine/Azacitidine-Aclarubicin Association |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | BCL-2 inhibitor |
| Target | BCL-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Venetoclax's mechanism of action involves binding to BCL-2, preventing its anti-apoptotic function, and thereby promoting cell death. Decitabine/Azacitidine-Aclarubicin combination induces DNA hypomethylation, leading to the reactivation of tumor suppressor genes and the promotion of apoptosis in cancer cells.
Approved indications
- Acute myeloid leukemia (AML)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venetoclax-Decitabine/Azacitidine-Aclarubicin Association CI brief — competitive landscape report
- Venetoclax-Decitabine/Azacitidine-Aclarubicin Association updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI
Frequently asked questions about Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
What is Venetoclax-Decitabine/Azacitidine-Aclarubicin Association?
How does Venetoclax-Decitabine/Azacitidine-Aclarubicin Association work?
What is Venetoclax-Decitabine/Azacitidine-Aclarubicin Association used for?
Who makes Venetoclax-Decitabine/Azacitidine-Aclarubicin Association?
What drug class is Venetoclax-Decitabine/Azacitidine-Aclarubicin Association in?
What development phase is Venetoclax-Decitabine/Azacitidine-Aclarubicin Association in?
What are the side effects of Venetoclax-Decitabine/Azacitidine-Aclarubicin Association?
What does Venetoclax-Decitabine/Azacitidine-Aclarubicin Association target?
Related
- Drug class: All BCL-2 inhibitor drugs
- Target: All drugs targeting BCL-2
- Manufacturer: The First Affiliated Hospital with Nanjing Medical University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML)
- Compare: Venetoclax-Decitabine/Azacitidine-Aclarubicin Association vs similar drugs
- Pricing: Venetoclax-Decitabine/Azacitidine-Aclarubicin Association cost, discount & access